You are here

Key figures

Extracts from the consolidated income statement

Summary of consolidated income statement K€.

CHANGE OF METHOD:
As a reminder, since 1 January 2016 the SIPH Group has applied the historical costs method (in accordance with revised standards IAS 41 and IAS 16) as the valuation method for biological assets and not the fair value method. Applying this method means that the volatility effect of the fair value method on the income statement is limited.

Thousands of euros 31/12/2016 31/12/2015 Revised (1) 31/12/2015 Published
Rubber sales 249 399 224 980 224 980
Other sales 18 468 22 005 22 005
TOTAL TURNOVER 267 866 246 984 246 984
Total cost of sold goods -207 383 -197 415 -197 234
Margin on direct costs 60 484 49 570 49 750
General expenses -22 720 -25 139 -25 139
Depreciation -18 196 -17 581 -14 283
Net agricultural investments -10 880
Fair value variation of biological assets 5 593
CURRENT OPERATING INCOME 18 848 6 850 5 042
+/- value from disposals and other operating income and expenses 631 -131 46
Other operational income and expenses -5 396 -7 961 -4 885
OPERATING INCOME 14 084 -1 242 203
Income on cash management and cash equivalent 5 266 484 484
Cost of gross financial debt -2 089 -2 222 -5 235
Cost of net financial debt 3 177 -1 738 -4 751
Income or expense on income tax -7 540 1 257 779
INCOME 9 721 -1 724 -3 769
attributable
- Group Income 6 867 -2 144 -2 613
- Income from minority interests 2 854 421 -1 156
9 721 -1 724 -3 769
Earnings per share: income from
Shareholders of the Company (in Euros per share)
- basic 1,36 -0,42 -0,52
- diluted 1,36 -0,42 -0,52

(1) after application of revised standards IAS 16 and IAS 41

SIPH Group’s Consolidated Balance Sheets

CHANGE OF METHOD:
As a reminder, since 1 January 2016 the SIPH Group has applied the historical costs method (in accordance with revised standards IAS 41 and IAS 16) as the valuation method for biological assets and not the fair value method. Applying this method means that the volatility effect of the fair value method on the income statement is limited.

In millions of Euros 2016 2015 (revised)(1) 2015 (published)
NON-CURRENT ASSETS 229,2 247,6 198,7
    GOODWILL 17,4 19,7 19,7
    BIOLOGICAL ASSETS 114,4 115,7 57,8
CURRENT ASSETS 134,4 114,8 114,8
    STOCKS of rubber 47,6 37,8 37,8
    CASH AND CASH EQUIVALENTS 25,3 29,2 29,2
TOTAL ASSETS 363,5 362,3 313,4
       
EQUITY 192,2 205,6 157,5
LONG TERM DEBT 61,0 57,6 57,6
SHORT TERM DEBT 54,8 51,9 51,9
NON-CURRENT LIABILITIES 12,4 12,3 11,5
CURRENT LIABILITIES 43,0 34,9 34,9
TOTAL LIABILITIES 363,5 362,3 313,4

(1) after application of revised standards IAS 16 and IAS 41

SIPH Group’s Consolidated Cash Flow Statements

In millions of Euros 2016 2015 (revised)(1) 2015 (published)
Cash flow 32,6 25,1 25,3
Taxes paid -2,4 -3,0 -3,0
Changes in working capital -18,9 2,0 2,0
CASH FLOW FROM OPERATING ACTIVITIES 11,3 24,0 24,2
Investments -18,2 -38,3 -35,5
Financial assets -0,1 0,1 0,1
Changes within the consolidation
CASH FLOW FROM INVESTMENTS -18,3 -38,1 -35,3
Dividends to minority interests of the subsidiaries
SIPH Dividends
New loans 0,3 31,5 31,5
Repayment of loans & interest -8,0 -8,0 -11,0
Other cash flows from financing activities 5,8 2,3 2,3
CASH FLOW FROM FINANCING -1,9 25,8 22,8
Changes in exchange rates -0,6 0,08 0,08
CHANGES IN CASH -9,5 11,8 11,8
CASH AT START OF YEAR 29,0 17,2 17,2
CASH AT YEAR END 19,5 29,0 29,0

(1) after application of revised standards IAS 16 and IAS 41

Site built by ImageVector in compliance with MiddleNext recommendations • Conditions of use